Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Product | Terms/Details (Date) |
| | |||
Acorda Therapeutics Inc.* | Rxpedite (joint venture between inChord Communications and Cardinal Health Inc.) | Fampridine-SR | Marketing agreement related to possible launch of sustained-release product; Rxpedite will manage all communications efforts (9/28) |
| |||
Althea Technologies Inc.* | Baxter Healthcare Corp. | Co-promotion agreement for Althea's plasmid DNA manufacturing services and both firms' contract fill and finish services | Althea will provide small batch services to customers through Phase III, and Baxter will service commercialization efforts (9/7) |
| |||
BioMarin Pharmaceuticals Inc. (BMRN) | Merck Eprova AG (subsidiary of Merck KGaA; Germany) | Manufacturing and supply agreement for BioMarin's Phenoptin (6R-BH4), a drug nearing clinical trials for phenylketonuria | BioMarin and Merck will share process development and manufacturing costs; Merck will supply product for clinical trials and would get royalties on commercial sales (11/20) |
| |||
Cellectis SA* (France) | Fermentas UAB (Lithuania) | The endonuclease I-SceI | Cellectis granted Fermentas a nonexclusive worldwide license for manufacturing and selling the endonuclease; terms were not disclosed (11/18) |
| |||
FeRx Inc.* | Laureate Pharma LLP | MTC-DOX | Laureate will provide fill and finishing services under the manufacturing agreement, terms of which were not disclosed (10/14) |
| |||
Codexis Inc. (subsidiary of Maxygen Inc.; MAXY) | Sandoz Inc. (unit of Novartis AG; Switzerland) | Sandoz compound | Collaboration to develop an improved process for manufacturing a Sandoz compound; Codex will get up-front and R&D funding, and potential milestone and royalty payments (10/27) |
| |||
EraGen Biosciences Inc. Inc.* | Itochu Corp. and CTC Laboratory Systems Corp. (both of Japan) | EraGen's phylogenomics product, Master Catalog | The two firms will exclusively distribute the product in Japan; terms were not disclosed (11/17) |
| |||
Labopharm Inc. (Canada; TSE:DDS) | CSC Pharmaceuticals Handels GmbH (Austria) | Once-daily version of the analgesic tramadol | Labopharm's European subsidiary granted GCS the right to market and sell the product in 14 Eastern European countries; Labopharm will supply product and earn a share of any revenues (11/6) |
| |||
Nabi Biopharmaceuticals (NABI) | Cambrex Corp. | Manufacturing agreement for StaphVax vaccine | Nabi granted Cambrex a 10-year renewable contract to manufacture the vaccine (10/9) |
| |||
Ortec International Inc. (OTT BB:ORTN) | Teva Pharmaceutical Industries Ltd. (Israel) | OrCel tissue-engineered product | Teva obtained a 10-year license to sell OrCel in Israel for wound healing and other dermatological applications; terms were not disclosed (10/23) |
| |||
Viragen Inc. (AMEX:VRA) | Pentafarma SA (Chile; subsidiary of Fresenius Medical Care) | Distribution agreement for Viragen's Multiferon | Pentafarma gained exclusive rights to sell the product in Chile; terms were not disclosed (11/17) |
| |||
ZymoGenetics Inc. (ZGEN) | Abbot Laboratories | Recombinant human thrombin | Abbott will be responsible for production of product for late-stage clinical studies and commercial sales; terms were not disclosed (10/2) |
| |||
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE: Toronto Stock Exchange. | |||